Accurate predictions across scales can transform drug development.
We envision the ability to accurately predict the effects of change, from molecules to organisms, using millions of natural experiments.
Biology first
Every individual, of every species, is unique. Put another way, Nature conducts an almost-infinite range of silent experiments. We are at a moment in history when our ability to read the results of these experiments has expanded beyond the imagination of our predecessors: we can generate data that uses natural variation that reveals the molecular mechanisms of disease.
The why not the what
Biology runs on causes, not correlations. By decoding the ‘why’ of living systems - cause and effect - we can reveal molecular targets that have been missed, overlooked or undervalued.
Thinking in the language of biology
The language of biology arose by chance from chaos, but is remarkably consistent across every lifeform on the planet. By leveraging the capability of AI to recognise complex patterns across long DNA sequences, we empower it to make discoveries that no human could make.
Bio x AI Team
World-leading biologists and computer scientists
Kenneth Baillie
Chief Executive Officer
Kenneth Baillie, FRSE FMedSci, is a visionary leader who bridges the gap between genomic discovery and clinical breakthroughs.
When every genomics group in the world was spending billions to solve the same problem, Baillie’s clinical and scientific insight put his team ahead: he was first to discover 75% of Covid-19 host genes. His genetics and computational biology work led directly to the discovery of baricitinib as an effective COVID-19 treatment - the first time in history that a host genetic discovery has led to an effective new drug treatment for any infectious disease.
He has secured over £100 million in career funding, is in the top 1% of highly-cited researchers worldwide. He is leveraging his unique expertise in genomics, biological systems, and medicine to lead Multiscale Labs to transform patients’ lives.
Konrad Rawlik
Chief Technical Officer
Konrad Rawlik, PhD, is a 10x quantitative methodology innovator.
Dr Rawlik won the biggest race in the history of genomics. The unprecedented data release from UK Biobank sparked a global contest to discover genetic mechanisms of hundreds of human diseases. Rawlik devised and implemented a method to conduct genome-wide analyses faster than any other group in the world.
Dr. Rawlik’s research bridges theoretical machine learning and real-world genomic analysis. As Multiscale’s Chief Technical Officer, he leads the development of our AI-driven biological modeling platform. His rare combination of deep technical expertise and proven business leadership makes him ideally suited to transform our vision of a comprehensive, cross-species biological model into reality.
Jonathan Millar
Chief Medical Officer
Jonathan Millar, MD PhD, brings a powerful combination of clinical expertise and computational innovation to his role as Multiscale’s Chief Medical Officer. As a Senior Research Fellow at the University of Edinburgh and Consultant in Intensive Care Medicine, he has pursued the integration of AI and omics technologies into therapeutic discovery and clinical trials.
Dr. Millar’s leadership of several international studies, demonstrates his ability to orchestrate complex, large-scale clinical research programs. His extensive work building global research networks across North America, Europe, Asia, and Australasia positions him uniquely at the intersection of international scientific collaboration and technological innovation.
At Multiscale, Dr. Millar harnesses his distinctive blend of clinical insight and computational expertise to drive the development of AI-powered solutions that decode biological complexity across species and scales.
Mirella Lapata
Head of AI Research
Mirella Lapata, FRSE, is a global deep learning pioneer. She is consistently ranked in the top 5 worldwide in Natural Language Processing. She pioneered deep learning for text generation, replacing rigid pipelines with trainable models. Her breakthroughs in planning-based methods reshaped the field. Lapata has won numerous awards, including a Turing fellowship, and the 2025 Ada Lovelace Award in Computer Science, the British Computer Society Karen Spärck Jones Award and election to Academia Europaea.
Her founding of the Edinburgh Laboratory for Integrated Artificial Intelligence (ELIAI) and strategic collaborations with tech leaders like Google DeepMind and Amazon demonstrate her ability to translate cutting-edge research into practical applications.
At Multiscale, Professor Lapata’s pioneering work in AI and language understanding is instrumental in decoding complex biological data across diverse life forms. Her expertise in developing sophisticated AI systems that can interpret and generate complex information is helping revolutionise our understanding of biological systems, from microscopic organisms to human disease.
Collaborate
Get in touch with our team